ORLANDO, Fla. – Edgewise Therapeutics, a biopharmaceutical company focused on muscle diseases, will present promising recent data on sevasemten, an investigational therapy for Becker muscular dystrophy, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, taking place March 8–11 at the Hilton Orlando. The presentations, including data from the ongoing MESA open-label extension trial, aim to shed light on the potential of sevasemten to slow the progression of this debilitating genetic condition. This represents a significant step forward in the search for effective treatments for Becker muscular dystrophy, a disease that progressively weakens muscles and limits mobility.
Sevasemten is designed to address the root cause of muscle breakdown in muscular dystrophies – contraction-induced muscle damage. In healthy muscle, the protein dystrophin provides protection during muscle contractions. However, in Becker and Duchenne muscular dystrophies, a lack of functional dystrophin leaves muscles vulnerable to injury with each contraction. Edgewise’s approach focuses on inhibiting rapid skeletal myosin, aiming to reduce the exaggerated muscle damage that occurs in the absence of dystrophin. The therapy has already received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for both Becker and Duchenne muscular dystrophy, as well as Fast Track designation from the FDA for Becker muscular dystrophy, highlighting its potential.
Edgewise to Highlight New Data at MDA Conference
At the MDA conference, Edgewise will host a lunch forum on Monday, March 9, 2026, at noon ET, titled “Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care.” The forum will feature insights from leading experts in the field, including Matthew Wicklund, M.D., FAAN, Professor of Neurology at UT Health San Antonio; Abby Bronson, M.B.A., Vice President of Patient Advocacy and External Innovation at Edgewise; and Amit Sachdev, M.D., M.S., Associate Chief Medical Officer at MSU Healthcare and Assistant Professor of Neuromuscular Medicine at Michigan State University. The discussion will be moderated by Roxana Donisa Dreghici, M.D., Vice President of Clinical Development at Edgewise. Registration for the forum is limited to conference attendees.
Beyond the forum, Edgewise will present several scientific posters detailing the latest research on sevasemten. One poster, titled “Long-term stabilization of function in Becker: Sevasemten prevented functional decline up to 3.5 years in MESA open-label extension” (477LB), will be presented on Tuesday, March 10, 2026, by Craig M. McDonald, M.D., Distinguished Professor and Chair at the UC Davis Health Department of Physical Medicine, and Rehabilitation. Another poster, “Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in CANYON” (470LB), will be presented on Monday, March 9, 2026, by Ben Barthel, Ph.D., of Edgewise. Additional posters will focus on patient-focused drug development and the impact of BMD and DMD mutations on female carriers.
Understanding the Impact on Patients
Edgewise is also prioritizing understanding the patient experience. A poster titled “Patient-focused drug development: Understanding the patient experience and meaningful treatment outcomes in Becker muscular dystrophy via interviews” (8S), presented by Abby Bronson on Sunday, March 8, 2026, will share insights gathered directly from individuals living with the condition. This reflects a growing emphasis within the pharmaceutical industry on incorporating patient perspectives into the development of new therapies. Further research, presented in the poster “Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration” (167M) by Luuli Tran, Ph.D., explores the impact of these mutations on female carriers, a population often overlooked in research.
The full program for the 2026 MDA Clinical and Scientific Conference is available at mdaconference.org. Edgewise plans to make the presentations and posters available on its website following the conference.
Edgewise Therapeutics is also developing other novel therapeutics, including EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure, demonstrating a broad commitment to addressing serious muscle and cardiac diseases. The company’s focus on muscle physiology aims to drive the development of innovative treatments for a range of debilitating conditions.
The presentations at the MDA conference represent the latest step in the clinical development of sevasemten. Investors and those following the company can find more information on the Edgewise Therapeutics website at edgewisetx.com or through their social media channels on LinkedIn, X, Facebook, and Instagram.
Disclaimer: The information provided in this article is for informational purposes only and does not constitute medical advice. Readers should consult with a qualified healthcare professional for any health concerns or before making any decisions related to their health or treatment.
The next key milestone for Edgewise Therapeutics will be the continued analysis of data from the ongoing clinical trials of sevasemten and the potential submission of a New Drug Application to regulatory authorities. Further updates will be shared as they turn into available. We encourage readers to share this information with those who may be affected by Becker muscular dystrophy and to engage in respectful discussion about the potential of new therapies.
